AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20488261 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin A supplementation)
Number of subjects: 888
Study 18560640 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish
Number of subjects: 149
Study 18560640 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride gel
Number of subjects: 149
Study 18560640 — intervention group
Group type: COMPARATOR
Intervention: Dental health education program
Number of subjects: 149
Study 16012211 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (Group 1)
Number of subjects: 20
Study 16012211 — intervention group
Group type: COMPARATOR
Intervention: Adper Prompt (Group 2)
Number of subjects: 20
Study 12401757 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 4 mg b.i.d.
Number of subjects: 203
Study 12401757 — intervention group
Group type: COMPARATOR
Intervention: Glyburide (GLB) titrated to mean 10.5 mg/day for the first 8 weeks
Number of subjects: 203
Study 10350385 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 2 g every 12 h for a minimum of 3 days and up to 14 days
Number of subjects: 151
Study 10350385 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 1 g every 12 h for a minimum of 3 days and up to 14 days
Number of subjects: 151
Study 10350385 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 151
Study 10350385 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 151
Study 9166486 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 300 IU/kg three times a week
Number of subjects: 30
Study 9166486 — intervention group
Group type: COMPARATOR
Intervention: Conventional supportive treatment alone
Number of subjects: 30
Study 1613829 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg/day rhGH
Number of subjects: 14
Study 1613829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6089540 — intervention group
Group type: EXPERIMENTAL
Intervention: lacto-ovo vegetarian diet
Number of subjects: 36
Study 31351998 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at Zusanli (ST‐36), Hegu (LI‐4), and Sanyingjiao (SP‐6)
Number of subjects: 90
Study 31351998 — intervention group
Group type: COMPARATOR
Intervention: Sham pressure (placebo group)
Number of subjects: 90
Study 31351998 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 90
Study 29641522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-surgical psychological assessment using STAI (State-Trait Anxiety Inventory) and HADS-A (Hospital Anxiety and Depression Scale - Anxiety)
Number of subjects: 398
Study 29641522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-surgical psychological assessment using MFI (Multidimensional Fatigue Inventory)
Number of subjects: 398
Study 29641522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-surgical psychological assessment using HADS-D (Hospital Anxiety and Depression Scale - Depression)
Number of subjects: 398
Study 29641522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-surgical psychological assessment using STAS (State-Trait Anger Scale)
Number of subjects: 398
Study 29641522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-surgical psychological assessment including self-efficacy and sex
Number of subjects: 398
Study 27893130 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient palliative care (n=81), seen by palliative care clinicians at least twice a week during HCT hospitalization.
Number of subjects: 160
Study 27893130 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient palliative care (n=81)
Number of subjects: 160
Study 27893130 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of patients in the intervention group
Number of subjects: 160
Study 27893130 — intervention group
Group type: COMPARATOR
Intervention: Standard transplant care (n=79)
Number of subjects: 160
Study 24354738 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium bicarbonate
Number of subjects: 60
Study 24354738 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Number of subjects: 60
Study 24354738 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 60
Study 23006657 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated clinic (n=1336)
Number of subjects: 2340
Study 23006657 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (n=668)
Number of subjects: 2340
Study 23006657 — intervention group
Group type: COMPARATOR
Intervention: Parramatta pathology centre without a reminder (n=334)
Number of subjects: 2340
Study 23006657 — intervention group
Group type: EXPERIMENTAL
Intervention: Parramatta pathology centre with a reminder (n=336)
Number of subjects: 2340
Study 23006657 — intervention group
Group type: COMPARATOR
Intervention: Pathology centres (n=1004)
Number of subjects: 2340
Study 23006657 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 2340
Study 23006657 — intervention group
Group type: COMPARATOR
Intervention: Comparison of dedicated clinics vs pathology centres
Number of subjects: 2340
Study 20208067 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-report of cardiovascular diagnoses
Number of subjects: 7640
Study 20208067 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual characteristics (e.g., choice of general practitioner, male gender, age)
Number of subjects: 7640
Study 17389624 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.67 +/- 0.14 mg/kg)
Number of subjects: 22
Study 17389624 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH, bolus of 1500 IU followed by infusion of 2750 IU)
Number of subjects: 22
Study 15549327 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU 450 mg/m2 and leucovorin 100 mg/m2 x 5 days every 4 weeks; six cycles (arm A)
Number of subjects: 145
Study 15549327 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h infusion of high-dose 5-FU/leucovorin 2,600 mg/m2 and 500 mg/m2, two cycles of six applications (arm B)
Number of subjects: 145
Study 15549327 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h infusion of high-dose 5-FU 2,600 mg/m2, two cycles of six applications (arm C)
Number of subjects: 145
Study 15549327 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 145
Study 12377751 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 362
Study 12377751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study 9928771 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic treatment (non-opioid or opioid analgesics, antidepressants, anticonvulsants, corticosteroids)
Number of subjects: 593
Study 9928771 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative antineoplastic treatment
Number of subjects: 593
Study 9928771 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve blocks
Number of subjects: 593
Study 9928771 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 593
Study 9928771 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 593
Study 9928771 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electric nerve stimulation
Number of subjects: 593
Study 7752902 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acids (PUFA) ethyl esters
Number of subjects: 20
Study 7752902 — intervention group
Group type: COMPARATOR
Intervention: olive oil (as placebo)
Number of subjects: 20
Study 2211170 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative rewarming period
Number of subjects: 36
Study 7011228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tined endocardial electrodes
Number of subjects: 34
Study 7011228 — intervention group
Group type: COMPARATOR
Intervention: Flange-tipped leads
Number of subjects: 34
Study 30816266 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro transcription of the DNA pool with RNA polymerase of interest
Number of subjects: 0
Study 30816266 — intervention group
Group type: EXPERIMENTAL
Intervention: T7 promoter variants
Number of subjects: 0
Study 30816266 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoter of cyanophage Syn5 RNA polymerase
Number of subjects: 0
Study 28601567 — intervention group
Group type: EXPERIMENTAL
Intervention: All evidence-based measures (prophylactic antibiotics within 60 minutes of cesarean delivery, chlorhexidine-alcohol for skin antisepsis, closure of subcutaneous layer if ≥2 cm, subcuticular skin closure with suture)
Number of subjects: 1082
Study 28601567 — intervention group
Group type: COMPARATOR
Intervention: No evidence-based measures
Number of subjects: 1082
Study 28601567 — intervention group
Group type: EXPERIMENTAL
Intervention: All evidence-based measures
Number of subjects: 1082
Study 28601567 — intervention group
Group type: EXPERIMENTAL
Intervention: Unscheduled cesarean delivery among those who received all evidence-based measures
Number of subjects: 1082
Study 28601567 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled cesarean delivery among those who received all evidence-based measures
Number of subjects: 1082
Study 26974889 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV4 + Tdap + bivalent rLP2086
Number of subjects: 2648
Study 26974889 — intervention group
Group type: COMPARATOR
Intervention: bivalent rLP2086 alone
Number of subjects: 2648
Study 25197015 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided surgery
Number of subjects: 59
Study 25197015 — intervention group
Group type: COMPARATOR
Intervention: Conventional implant placement
Number of subjects: 59
Study 25197015 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study 22458821 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT)
Number of subjects: 43
Study 22458821 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (ST)
Number of subjects: 43
Study 22458821 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (CBT)
Number of subjects: 43
Study 22458821 — intervention group
Group type: COMPARATOR
Intervention: No training (NT)
Number of subjects: 43
Study 21169160 — intervention group
Group type: EXPERIMENTAL
Intervention: Online community arm
Number of subjects: 324
Study 21169160 — intervention group
Group type: COMPARATOR
Intervention: No online community arm
Number of subjects: 324
Study 17937565 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary soy supplements (part of a randomized, placebo-controlled trial)
Number of subjects: 216
Study 17937565 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group in the trial)
Number of subjects: 216
Study 15743397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone (200 mg over a 3 h period)
Number of subjects: 12
Study 15743397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial hydrocortisone
Number of subjects: 12
Study 15743397 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study 11990732 — intervention group
Group type: COMPARATOR
Intervention: Nandrolone decanoate (ND) 200 mg/week, intramuscularly for 8 weeks
Number of subjects: 34
Study 11990732 — intervention group
Group type: EXPERIMENTAL
Intervention: Various AASs at supratherapeutic dosages
Number of subjects: 34
Study 9655532 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (oral, for 5 days)
Number of subjects: 29
Study 9655532 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral, for 5 days)
Number of subjects: 29
Study 7653817 — intervention group
Group type: COMPARATOR
Intervention: 3‐in‐1 block with 40 mL of 1.5% lidocaine plus epinephrine (n = 13)
Number of subjects: 44
Study 7653817 — intervention group
Group type: COMPARATOR
Intervention: 3‐in‐1 block with 50 mL of 1.5% lidocaine plus epinephrine (n = 11)
Number of subjects: 44
Study 7653817 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct obturator nerve block with 10 mL of 2% lidocaine plus epinephrine (n = 20)
Number of subjects: 44
Study 2683439 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous application of 0.1% fluprednidene-21-acetate twice a day
Number of subjects: 44
Study 2683439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent therapy with 1 day intermission (15 patients)
Number of subjects: 44
Study 2683439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent therapy with 2 days intermission (16 patients)
Number of subjects: 44
Study 2683439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent therapy with 3 days intermission (13 patients)
Number of subjects: 44
Study 2683439 — intervention group
Group type: COMPARATOR
Intervention: Fluprednidene treatment in eczema patients
Number of subjects: 44
Study 2683439 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol-17-propionate
Number of subjects: 44
Study 335225 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined calcium and vitamin D‐2 phosphate treatment
Number of subjects: 135
Study 335225 — intervention group
Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 135
Study 335225 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and phosphate treatment
Number of subjects: 135
Study 31977576 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 23964
Study 31977576 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 23964
Study 31977576 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 23964
Study 31399438 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (≤1.8 mg daily; n = 4,668)
Number of subjects: 9340
Study 31399438 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 4,672)
Number of subjects: 9340
Study 31399438 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (n = 4,668)
Number of subjects: 9340
Study 28009690 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional Er:YAG laser
Number of subjects: 30
Study 28009690 — intervention group
Group type: COMPARATOR
Intervention: Microneedling
Number of subjects: 30
Study 26348751 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of elemental iron (as ferrous fumarate)
Number of subjects: 470
Study 26348751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 470
Study 22684652 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient cocktail containing physiological doses of antioxidant vitamins and trace minerals
Number of subjects: 37
Study 22684652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 21659294 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 198
Study 21659294 — intervention group
Group type: COMPARATOR
Intervention: Standard Clinical Case Management (SCCM)
Number of subjects: 198
Study 18820317 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 168
Study 17107402 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg plus montelukast 10 mg
Number of subjects: 36
Study 17107402 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg plus placebo
Number of subjects: 36
Study 17107402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15174894 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral modified-release clarithromycin 500 mg/day for 3 months
Number of subjects: 67
Study 15174894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 11409816 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention, additional cost of $124.17
Number of subjects: 0
Study 11409816 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention, cost of $187.52
Number of subjects: 0
Study 9248762 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP-DH) 500 micrograms b.i.d. for 7 days
Number of subjects: 81
Study 9248762 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP-DH) 1000 micrograms b.i.d. for 7 days
Number of subjects: 81
Study 9248762 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD-TBH) 400 micrograms b.i.d. for 7 days
Number of subjects: 81
Study 9248762 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD-TBH) 800 micrograms b.i.d. for 7 days
Number of subjects: 81
Study 9248762 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP-DH) ED50
Number of subjects: 81
Study 9248762 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD-TBH) ED50
Number of subjects: 81
Study 9248762 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP-DH) morning plasma cortisol levels
Number of subjects: 81
Study 9248762 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD-TBH) morning plasma cortisol levels
Number of subjects: 81
Study 9248762 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP-DH) cortisol suppression 12-24 h after last dose
Number of subjects: 81
Study 9248762 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD-TBH) cortisol suppression 12-24 h after last dose
Number of subjects: 81
Study 8507346 — intervention group
Group type: EXPERIMENTAL
Intervention: MDE (140 mg)
Number of subjects: 8
Study 8507346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3113399 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl citrate 50 micrograms/kg
Number of subjects: 23
Study 3113399 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl citrate 100 micrograms/kg
Number of subjects: 23
Study 3113399 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from both groups
Number of subjects: 23
Study 28731871 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor‐Assisted Problem Solving (CAPS)
Number of subjects: 132
Study 28731871 — intervention group
Group type: COMPARATOR
Intervention: Internet resource comparison (IRC)
Number of subjects: 132
Study 26546591 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing dry weight and lowering home BP
Number of subjects: 133
Study 26546591 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering home BP
Number of subjects: 133
Study 26546591 — intervention group
Group type: EXPERIMENTAL
Intervention: Uremic symptoms
Number of subjects: 133
Study 24188897 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (100mg elemental Zn daily for 60 days)
Number of subjects: 60
Study 24188897 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60
Study 23276723 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 12
Study 20846599 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg maintenance dose (MD)
Number of subjects: 100
Study 20846599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg maintenance dose (MD)
Number of subjects: 100
Study 20846599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg loading dose (LD) + 10 mg maintenance dose (MD)
Number of subjects: 100
Study 20846599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel loading dose (LD)
Number of subjects: 100
Study 18718780 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial doses of doxycycline for 6 months
Number of subjects: 11
Study 18718780 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 11
Study 16423669 — intervention group
Group type: EXPERIMENTAL
Intervention: Color encoding of endocardial motion
Number of subjects: 117
Study 15300731 — intervention group
Group type: EXPERIMENTAL
Intervention: EMF exposure from a 902 MHz mobile phone
Number of subjects: 64
Study 15300731 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 64
Study 11780726 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game training using the symbolic method with the intention of making progress in actual putting
Number of subjects: 0
Study 11780726 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game training using the symbolic method with the intention of simply enjoying the game
Number of subjects: 0
Study 11780726 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game training using the analogue method
Number of subjects: 0
Study 11780726 — intervention group
Group type: COMPARATOR
Intervention: Control group (enjoyment group) using the analogue method
Number of subjects: 0
Study 9034286 — intervention group
Group type: EXPERIMENTAL
Intervention: IV rhG-CSF at dosages of 5 or 10 microg/kg a day for 10 or more days
Number of subjects: 12
Study 9034286 — intervention group
Group type: EXPERIMENTAL
Intervention: IV rhG-CSF
Number of subjects: 12
Study 8475720 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxidex
Number of subjects: 89
Study 8475720 — intervention group
Group type: EXPERIMENTAL
Intervention: Pred‐Forte 1%
Number of subjects: 89
Study 8475720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 3772891 — intervention group
Group type: EXPERIMENTAL
Intervention: Single perioperative dose of mezlocillin
Number of subjects: 158
Study 3772891 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of mezlocillin
Number of subjects: 158
Study 3772891 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of cefoxitin
Number of subjects: 158
Study 31035841 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic (2.3% NaCl) sea water
Number of subjects: 30
Study 31035841 — intervention group
Group type: COMPARATOR
Intervention: Isotonic (0.9% NaCl) sea water
Number of subjects: 30
Study 30041235 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 revolutions during EBUS-TBNA
Number of subjects: 150
Study 30041235 — intervention group
Group type: COMPARATOR
Intervention: 20 revolutions during EBUS-TBNA
Number of subjects: 150
Study 26832658 — intervention group
Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 4 weeks (2q4)
Number of subjects: 865
Study 26832658 — intervention group
Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 8 weeks after 5 monthly doses (2q8)
Number of subjects: 865
Study 26832658 — intervention group
Group type: COMPARATOR
Intervention: Macular laser photocoagulation
Number of subjects: 865
Study 26832658 — intervention group
Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 4 weeks (2q4) in patients without prior anti-VEGF treatment
Number of subjects: 865
Study 26832658 — intervention group
Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 8 weeks after 5 monthly doses (2q8) in patients without prior anti-VEGF treatment
Number of subjects: 865